Alpha psychiatryPub Date : 2026-09-07eCollection Date: 2026-10-01DOI: 10.31083/AP52709
Peng Cui, Guoshuai Luo, Xiangyang Zhang
{"title":"Prevalence and Influencing Factors of Comorbid Major Depressive Disorder in Elderly Schizophrenia: A Multicenter Cross-Sectional Study.","authors":"Peng Cui, Guoshuai Luo, Xiangyang Zhang","doi":"10.31083/AP52709","DOIUrl":"10.31083/AP52709","url":null,"abstract":"<p><strong>Background: </strong>This multicenter cross-sectional study aimed to determine the prevalence, clinical correlates, and determinants of comorbid major depressive disorder (MDD) in elderly patients with schizophrenia (SZ), addressing a critical gap in understanding late-life dual diagnosis.</p><p><strong>Methods: </strong>We recruited 274 elderly SZ patients (≥60 years) from nine psychiatric centers across China. Diagnoses of schizophrenia and concurrent MDD were confirmed using the Structured Clinical Interview for DSM-5 (SCID-5). Depressive severity was assessed with the Hamilton Depression Rating Scale (HAMD-17), and psychotic symptoms with the Positive and Negative Syndrome Scale (PANSS). Multivariate analyses (binary/ordinal logistic regression, partial correlations), adjusted for age, sex, education, and antipsychotic dosage (chlorpromazine equivalents), identified factors associated with MDD comorbidity and severity.</p><p><strong>Results: </strong>The prevalence of comorbid MDD was 29.2% (80/274). PANSS General Psychopathology subscale scores (odds ratio [OR] = 1.064, 95% confidence interval [CI]: 1.013-1.118, <i>p</i> = 0.012) and PANSS Total Score (OR = 1.062, 95% CI: 1.008-1.152, <i>p</i> = 0.002) were significantly associated with MDD comorbidity. HAMD-17 scores exhibited strong positive correlations with PANSS General Psychopathology (r = 0.402, <i>p</i> < 0.001) and PANSS Total Score (r = 0.310, <i>p</i> < 0.001) after adjustment for covariates. No significant association was found between HAMD-17 and the PANSS Negative subscale (r = 0.606, <i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>In this multicenter sample of elderly Chinese inpatients with schizophrenia, nearly one-third of participants had comorbid MDD. The robust association between overall psychopathology severity, as measured by the PANSS Total Score and General Psychopathology subscale, and comorbid MDD supports the presence of transdiagnostic mechanisms in late-life schizophrenia. PANSS assessment, particularly the General Psychopathology subscale, may serve as a clinically informative adjunct to routine evaluation for identifying elderly patients with schizophrenia who are at increased risk of comorbid depression. However, its modest discriminative performance (area under the curve [AUC] ≈ 0.60) precludes its use as a standalone screening tool<i>.</i></p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"52709"},"PeriodicalIF":2.9,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-09-03eCollection Date: 2026-10-01DOI: 10.31083/AP48750
Wenzhong Liu, Yang Fan, Pingping Ma, Ting Song, Bo Liu, Kezhi Liu, Youguo Tan
{"title":"Advancing Repetitive Transcranial Magnetic Stimulation for Depression: Novel Protocols, Precision Targeting, and Future Directions.","authors":"Wenzhong Liu, Yang Fan, Pingping Ma, Ting Song, Bo Liu, Kezhi Liu, Youguo Tan","doi":"10.31083/AP48750","DOIUrl":"10.31083/AP48750","url":null,"abstract":"<p><p>Major depressive disorder (MDD) remains a significant global health challenge, with substantial limitations inherent in current pharmacotherapeutic and psychotherapeutic approaches. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a safe, effective, and non-invasive neuromodulation therapy, particularly for treatment-resistant depression (TRD). However, conventional rTMS is limited by long treatment duration and variable interindividual efficacy. This expert opinion examines recent advances in rTMS optimization strategies aimed at overcoming these limitations. Key areas of progress include the development of novel stimulation protocols such as theta-burst stimulation (TBS); accelerated regimens and priming TMS; the use of magnetic resonance imaging (MRI)-guided TMS; and the integration of closed-loop systems using real-time electroencephalography (EEG) or functional near-infrared spectroscopy (fNIRS) feedback. Additionally, technological innovations, including robot-assisted TMS and wearable devices, promise to enhance targeting accuracy and treatment accessibility. Despite these developments, significant challenges impede clinical translation, including the high cost of personalized protocols, insufficient standardization and validation of novel approaches, and technical barriers to closed-loop implementation. Future efforts should focus on cost reduction, large-scale randomized controlled trials, biomarker development, and device portability. Ultimately, optimized rTMS shows significant potential to become a more efficient, precise, and accessible cornerstone of depression therapy.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"48750"},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Functional and Effective Connectivity Characteristics of the Dorsolateral Prefrontal Cortex in Drug-Naïve Patients with Generalized Anxiety Disorder.","authors":"Lijuan Yang, Fang He, Danfeng Yuan, Ting Yang, Liyang Zhang, Yu Chen, Jia Luo, Ying Li, Xiangyun Yang, Zhanjiang Li","doi":"10.31083/AP51187","DOIUrl":"10.31083/AP51187","url":null,"abstract":"<p><strong>Background: </strong>The dorsolateral prefrontal cortex (dLPFC) is a key brain region involved in cognitive control and emotional regulation and has been implicated in the pathophysiology of generalized anxiety disorder (GAD). This study used resting-state functional magnetic resonance imaging (rs-fMRI) to investigate functional connectivity (FC) and effective connectivity (EC) patterns of the bilateral dLPFC in drug-naïve patients with GAD. In addition, the relationships between abnormal connectivity patterns, anxiety symptoms, and attentional bias (AB) were examined.</p><p><strong>Methods: </strong>A total of 40 patients with GAD and 40 healthy controls (HCs) were recruited. Clinical symptoms in the GAD group were assessed using the Hamilton Anxiety Rating Scale (HAMA), the 17-item Hamilton Depression Rating Scale (HAMD-17), and the Generalized Anxiety Disorder-7 (GAD-7) scale. Attentional bias toward negative stimuli was evaluated using the dot-probe task and the emotional Stroop task. Independent-samples <i>t</i>-tests were performed to compare whole-brain voxel-wise FC and EC differences based on bilateral dLPFC regions of interest (ROIs) between the two groups. Partial correlation analyses, controlling for the duration of the current episode, were conducted to examine associations between aberrant FC/EC values and clinical symptoms or attentional bias in patients with GAD.</p><p><strong>Results: </strong>Compared with healthy controls, patients with GAD exhibited increased FC between the dLPFC and the medial superior frontal gyrus, inferior parietal gyrus, and left precentral gyrus. In addition, patients with GAD showed reduced directional (Granger-causal) connectivity from the dLPFC to the caudate nucleus, thalamus, and BA37, as well as from the left postcentral gyrus to the dLPFC (voxel-level <i>p</i> < 0.01; cluster-level Gaussian random field [GRF]-corrected <i>p</i> < 0.05). Correlation analyses revealed that dLPFC-based FC and EC values were significantly associated with anxiety symptom severity and attentional bias to varying degrees (r = -0.515 to 0.584, <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>This study identified widespread abnormalities in resting-state FC and EC involving the bilateral dLPFC in patients with GAD. Aberrant FC and EC patterns were closely associated with anxiety symptoms and attentional bias, further supporting the anxiety network hypothesis and highlighting the central role of the dLPFC within anxiety-related neural circuits. These findings provide preliminary neuroimaging evidence for the cognitive model of GAD and suggest that attentional bias toward threat-related stimuli may play a critical role in the pathogenesis of the disorder.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"51187"},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review.","authors":"Zhen-Juan Qin, Xiao-Ming Li, Jia-Bao Li, Zhi Li, Xin Wei, Hui-Lin Hu, Yu-Jiao Chen, Su-Rong Xu, Zhi-Yuan Xie, Xin-Hu Yang, Wen-Juan Dai, Yu-Hua Wei","doi":"10.31083/AP48866","DOIUrl":"10.31083/AP48866","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic efficacy and safety of intravenous ketamine or esketamine in adolescents with major depressive disorder (MDD) remain insufficiently defined. This systematic review of randomized controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of intravenous ketamine or esketamine in this population.</p><p><strong>Methods: </strong>A comprehensive search of four international databases (PubMed, EMBASE, PsycINFO, and the Cochrane Library) was conducted to identify RCTs comparing intravenous ketamine or esketamine with intravenous midazolam in adolescents with MDD.</p><p><strong>Results: </strong>Three RCTs involving a total of 134 adolescents with MDD were included. Two trials assessed the antidepressant effects of intravenous ketamine compared with intravenous midazolam, with inconsistent findings. No significant advantage of intravenous ketamine over intravenous midazolam was observed in reducing anxiety symptoms (1 RCT). One trial compared intravenous esketamine with intravenous midazolam and evaluated antidepressant, anti-suicidal, and neurocognitive outcomes, demonstrating the superiority of intravenous esketamine. Both intravenous ketamine and intravenous esketamine were associated with significantly higher rates of dissociative symptoms (1 RCT each), and intravenous esketamine was also linked to a higher incidence of psychopathological symptoms (1 RCT). Systematic reporting of adverse events was provided in only one of the three included RCTs.</p><p><strong>Conclusions: </strong>Given the limited number of studies, small sample sizes, and methodological heterogeneity of the available RCTs, the current evidence base remains preliminary and insufficient to support definitive conclusions regarding the efficacy and safety of intravenous ketamine/esketamine in adolescents with MDD. These findings highlight the need for further adequately powered RCTs to establish robust and clinically meaningful evidence.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"48866"},"PeriodicalIF":2.9,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-08-24eCollection Date: 2026-08-01DOI: 10.31083/AP53282
Alberto Garoli, Alessandro Greco
{"title":"Shielding the First 24 Postnatal Months of Life: A Proposal for a Prospective Cohort Study of Early-Life Electromagnetic Exposure and Autism Risk.","authors":"Alberto Garoli, Alessandro Greco","doi":"10.31083/AP53282","DOIUrl":"10.31083/AP53282","url":null,"abstract":"<p><strong>Background: </strong>Autism Spectrum Disorder (ASD) involves Mirror Neuron System (MNS) dysfunction, driving core social and imitative impairments. Systemic physiological alterations such as autonomic dysregulation, mitochondrial dysfunction and neuroinflammation are known to impair synchronization and plasticity of neuronal clusters. A less-evident environmental cofactor, coinciding with rising ASD prevalence, is the considerable world-wide increase in electromagnetic radiation (EMR) overall exposure among children. Experimental evidence shows how low-intensity EMR influences cellular processes, via voltage-gated calcium channels (VGCCs), oxidative stress, and mitochondrial metabolism. The Resonant Convergence framework, allow to predict how chronic EMR exposure during the first 24 postnatal months of life can act as a factor in ASD pathogenesis. The best candidate mechanism is chronic Ion Cyclotron Resonance (ICR) detuning the Ca<sup>2+</sup>-calmodulin pathway, thus disrupting MNS synchronization.</p><p><strong>Methods and analysis: </strong>A prospective observational pilot cohort study (24-month follow-up) proposes to enroll 1000 full-term newborns into two arms: an EMR-reduced cohort (n = 500, rest and sleep-phase Faraday shielding) and a standard exposure cohort (n = 500). Exposure is quantified via radiofrequency (RF)/extremely low frequency(ELF) measurements, proximity analysis, device inventories and wearable dosimetry. The primary endpoint is a continuous neurodevelopmental trajectory score (joint attention, language, electroencephalogram (EEG) mu-rhythm); binary ASD diagnosis (Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Autism Diagnostic Interview-Revised (ADI-R)) is a secondary, exploratory endpoint. Moreover, an optional genomic screening will evaluate gene-environment interactions within extremely low-frequency electromagnetic field (ELF-EMF) vulnerable pathways, including ASD-associated genes upregulated by RF via bromodomain and extraterminal protein (BET)-mediated epigenetic mechanisms. Analyses will employ risk ratios, Fisher's exact tests and logistic regression adjusted for confounders; mixed-effects and Bayesian modeling will evaluate longitudinal outcomes and exposure reduction effects. Given a 2-3% baseline prevalence, approximately 20-30 ASD cases are expected. The study is therefore powered for exploratory signal detection rather than definitive causal inference, providing the critical baseline data required to justify and design future confirmatory trials. Sex-stratified modeling will address the 4:1 male-to-female prevalence ratio.</p><p><strong>Ethics and dissemination: </strong>Ethics committee approval is not yet sought; full protocol review and approval will be obtained prior to the study initiation, in strict accordance with the Declaration of Helsinki. Written parental informed consent will be mandatory for all participants prior to enrollment. Study findings and methodological mil","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"53282"},"PeriodicalIF":2.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-08-24eCollection Date: 2026-08-01DOI: 10.31083/AP54760
George Anderson
{"title":"Low Dose Ketamine Preconditions Astrocyte Mitochondria to Achieve Antidepressant Efficacy via Adenosine, Humanin, and Melatonin Upregulation and Efflux.","authors":"George Anderson","doi":"10.31083/AP54760","DOIUrl":"10.31083/AP54760","url":null,"abstract":"<p><p>Understanding the physiological changes induced by ketamine in mood disorders, while reducing its side effects, is likely to contribute to a more comprehensive understanding of the physiology underlying mood disorders, as well as to the development of faster-acting and more efficacious antidepressant treatments. An extensive review of the literature on ketamine and the pathophysiology of depression indicates that ketamine's antidepressant efficacy has classically been attributed to noncompetitive antagonism of the n-methyl-d-aspartate receptor (NMDAR) on the neuronal postsynaptic membrane, thereby reducing excessive Ca²⁺ influx through the NMDAR channel. However, recent evidence suggests that ketamine's antidepressant efficacy is mediated not by synaptic NMDAR antagonism but rather by its direct effects on mitochondrial function, arising from its amphiphilic structure. It is proposed that astrocyte mitochondria represent the primary target of ketamine, with the broader effects induced by ketamine occurring downstream of the optimization of astrocyte mitochondrial function and, consequently, astrocyte function. Developmental stress and trauma are proposed to differentially prime specific regions of the central nervous system, rendering them more susceptible to subsequent stressors through the epigenetic regulation of astrocytes. This process increases astrocyte reactivity and dysregulates astrocyte mitochondrial function in response to subsequent stressors, while also increasing blood-brain barrier permeability within these regions. At stress-vulnerable sites, ketamine may upregulate adenosine, humanin, and melatonin, thereby restoring astrocyte function and attenuating inflammatory activity within the local astrocytic microenvironment, including microglia, neurons, and oligodendrocytes. Ketamine's modulation of mitochondrial function is proposed to be mediated via NMDARs located on the inner mitochondrial membrane, leading to alterations in mitochondrial ionic regulation that enhance astrocyte mitochondrial resilience to stress, possibly through a preconditioning mechanism. Ketamine-induced increases in melatonin and humanin are proposed to suppress microglial activation, promote white matter remyelination, and restore neuronal activity, as well as patterned intercellular and interregional communication. This hypothesis-driven overview evaluates ketamine's capacity to restore astrocyte mitochondrial function and thereby counteract the consequences of developmental stress and trauma that underlie vulnerability to subsequent stress-induced depression.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"54760"},"PeriodicalIF":2.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effect of Acute Psychotic Period on Physiological Values Measured in Blood in Male Patients With Schizophrenia.","authors":"Guler Celikel, Suat Yalcin, Tevfik Kalelioglu, Nesrin Karamustafalioglu","doi":"10.31083/AP53389","DOIUrl":"10.31083/AP53389","url":null,"abstract":"<p><strong>Background: </strong>There is increasing evidence that plasma osmolarity is an independent prognostic factor associated with mortality in patients with cardiovascular disease. Whole blood viscosity (WBV) is also associated with established cardiometabolic risk factors for cardiovascular disease. The present study aimed to investigate the effects of the acute phase of schizophrenia on physiological parameters, including WBV and plasma osmolarity, in male patients with schizophrenia.</p><p><strong>Methods: </strong>A total of 121 male patients with schizophrenia were included in this study. Routine blood test results were obtained from hospital records, and the laboratory values required for the calculation of viscosity and osmolarity were recorded. Laboratory data from the patients' most recent acute exacerbation were retrieved from hospital records and used as the acute-phase data.</p><p><strong>Results: </strong>There was no statistically significant difference in serum osmolarity between the acute and remission phases (<i>p</i> = 0.360). Blood urea nitrogen (BUN) and glucose levels were significantly higher during the remission phase, whereas sodium levels were significantly higher during the acute phase. No significant differences were observed in WBV values between the acute and remission phases (<i>p</i> > 0.05). Furthermore, there were no significant differences in WBV-related parameters, including hematocrit (HCT) and total protein, between the two phases. Low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, and triglyceride levels were significantly higher during the remission phase.</p><p><strong>Conclusions: </strong>Although differences were observed in osmolarity-related parameters and viscosity-associated metabolic variables between the acute and remission phases in male patients with schizophrenia, no statistically significant differences were found in serum osmolarity or WBV between the two phases.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"53389"},"PeriodicalIF":2.9,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-08-20eCollection Date: 2026-08-01DOI: 10.31083/AP53298
Iván Barrios, Julio Torales, Sandra Blanco, Carlos Manuel Giménez-Barboza, Brenda Mikaela Monges-Guerrero, Axel Verón-Otero, Gladys Mercedes Estigarribia Sanabria, Eva Natalia Giménez-Legal, João Mauricio Castaldelli-Maia, Antonio Ventriglio
{"title":"Artificial Intelligence Chatbot Dependence, Anxiety, and Depressive Symptoms in University Students: Initial Psychometric Evaluation of the Artificial Intelligence Chatbot Dependence Scale (AICDS) in Spanish.","authors":"Iván Barrios, Julio Torales, Sandra Blanco, Carlos Manuel Giménez-Barboza, Brenda Mikaela Monges-Guerrero, Axel Verón-Otero, Gladys Mercedes Estigarribia Sanabria, Eva Natalia Giménez-Legal, João Mauricio Castaldelli-Maia, Antonio Ventriglio","doi":"10.31083/AP53298","DOIUrl":"10.31083/AP53298","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) chatbots are rapidly becoming integrated into higher education, supporting human-computer interaction, knowledge explanation, rapid access to information, access to online learning resources, and personalized learning pathways. However, little is known about potential patterns of dependence on these technologies and their relationship with anxiety and depressive symptoms. This study aimed to conduct an initial psychometric evaluation of the Spanish version of the Artificial Intelligence Chatbot Dependence Scale (AICDS) and to explore its association with anxiety and depressive symptoms among university students.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among 200 university students from Santa Rosa del Aguaray, Paraguay. Participants completed the AICDS together with screening measures of anxiety and depressive symptoms. Data were analyzed using R version 4.5.3. Confirmatory factor analysis using diagonally weighted least squares estimation with robust standard errors was performed to examine the scale's factor structure, and multiple linear regression models were used to evaluate associations between AICDS scores and anxiety and depressive symptoms.</p><p><strong>Results: </strong>The findings supported a unidimensional factor structure with acceptable-to-good model fit and high internal consistency (Cronbach's α = 0.833; McDonald's ω = 0.903). Fully standardized factor loadings ranged from 0.538 to 0.873. In bivariate analyses, students who screened positive for anxiety symptoms had higher AICDS scores than those who screened negative, although the effect size was small. However, this association was not maintained after adjustment for sociodemographic and academic covariates in multiple regression models. No significant association was observed between AICDS scores and depressive symptoms under two-tailed testing.</p><p><strong>Conclusions: </strong>These findings provide preliminary evidence supporting the internal consistency and factorial validity of the Spanish version of the AICDS in this sample. However, associations between AI chatbot dependence and anxiety or depressive symptoms were weak and not robust after adjustment. Further longitudinal and psychometric research is needed before broader conclusions can be drawn about the mental health implications of AI chatbot dependence among university students.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"53298"},"PeriodicalIF":2.9,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-08-20eCollection Date: 2026-08-01DOI: 10.31083/AP51895
Anna Basińska-Szafrańska
{"title":"Longer Duration of Drug Elimination and Withdrawal Symptoms in Overweight Patients Undergoing Detoxification for Benzodiazepine Dependence.","authors":"Anna Basińska-Szafrańska","doi":"10.31083/AP51895","DOIUrl":"10.31083/AP51895","url":null,"abstract":"<p><strong>Background: </strong>In patients undergoing detoxification for benzodiazepine (BZD) dependence, withdrawal symptoms frequently persist into the low-concentration phase following drug discontinuation. Prolonged drug elimination may extend the duration of required medical supervision. Because lipophilic BZDs can accumulate in adipose tissue and be released gradually during detoxification, overweight patients may experience delayed elimination. This study quantitatively examined whether BZD elimination and the duration of withdrawal symptoms are prolonged in overweight patients.</p><p><strong>Methods: </strong>From 508 records of concentration-monitored detoxification, a retrospective sample of 290 inpatients matched for diet and physical activity was selected. All patients underwent detoxification according to the SAER protocol (Satiation, Anti-accumulation paradigm, Elimination, and Readaptation). Following (S) satiation with diazepam, further unnecessary (A) accumulation was prevented through aggressive day-by-day dose reductions guided by serum concentration monitoring. Subsequent tapering, leading to effective (E) elimination, was adjusted according to the evolving intensity of withdrawal symptoms, characterized by episodes of peak severity (withdrawal crises) interspersed with periods of relative relief. Completion of (R) readaptation was defined by the cessation of withdrawal symptoms after elimination. The duration of effective elimination, from peak serum concentration to undetectable levels, with particular attention to the post-discontinuation phase, was recorded. Concomitant medications known to influence BZD elimination were identified. Elimination parameters and the timing of clinically significant withdrawal crises were analyzed in relation to patients' body mass index (BMI).</p><p><strong>Results: </strong>Elimination duration was positively correlated with BMI (ρ = 0.39, <i>p</i> < 0.001). The timing of the strongest and/or the final crises also showed weak but significant positive correlations with BMI in the overall sample (ρ = 0.18 and 0.15, <i>p</i> < 0.01 and < 0.05 cutoff, respectively), and within the identified co-medication subgroups, including the valproate, carbamazepine, and no-modifier groups (ρ = 0.19-0.26, all <i>p</i> < 0.05). These associations accounted for a small proportion of the variance in overall time to withdrawal crisis (R<sup>2</sup> = 0.02-0.07). Nevertheless, they translated into an additional 8-11 days of necessary monitored care among obese patients. Elimination duration was further prolonged in patients receiving valproate. Extended elimination was not associated with reduced withdrawal symptom severity.</p><p><strong>Conclusions: </strong>Among patients undergoing detoxification for BZD dependence, higher BMI was associated with prolonged drug elimination and a longer duration of recurring withdrawal crises, without attenuation of symptom severity. Although the observed associations were m","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"51895"},"PeriodicalIF":2.9,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-08-19eCollection Date: 2026-08-01DOI: 10.31083/AP52900
Dario Morra, Gianluca Ficca, Giuseppe Barbato
{"title":"Polysomnographic Parameters in Schizoaffective Disorder: A Systematic Review and Meta-Analysis.","authors":"Dario Morra, Gianluca Ficca, Giuseppe Barbato","doi":"10.31083/AP52900","DOIUrl":"10.31083/AP52900","url":null,"abstract":"<p><strong>Background: </strong>Schizoaffective disorder (SZA) is a severe psychiatric condition characterized by overlapping affective and psychotic features; however, its sleep architecture remains poorly characterized. This systematic review and meta-analysis compared polysomnographic findings in drug-free patients with SZA with those of healthy controls (HC), patients with schizophrenia (SCZ), and patients with major depressive disorder (MDD).</p><p><strong>Methods: </strong>An extensive database search identified 40 studies. Nine case-control studies including 79 patients with SZA, 88 patients with SCZ, 79 HC, and 131 patients with MDD were included in the meta-analyses. Total sleep time, sleep efficiency, sleep latency, wake after sleep onset, and rapid-eye-movement (REM) and non-REM (NREM) sleep variables were analyzed. The primary outcome measure was the standardized mean difference (SMD). Data were analyzed using a random-effects model. Publication bias was assessed using Egger's regression test and funnel plot asymmetry.</p><p><strong>Results: </strong>Compared with HC, patients with SZA showed reduced total sleep time, increased sleep latency and wakefulness after sleep onset, reduced REM sleep duration, shortened REM latency, and reduced stage 4 sleep duration and percentage. Patients with SZA differed from those with MDD only in exhibiting increased sleep latency, whereas no significant differences were observed between patients with SZA and those with SCZ.</p><p><strong>Conclusions: </strong>Polysomnographic abnormalities in SZA demonstrate a general pattern of sleep disruption compared with HC, without clear differentiation from SCZ or MDD. Overall, current evidence does not support sleep architecture as a reliable biomarker for distinguishing SZA from related psychotic or affective disorders. These findings should be considered exploratory, given the small sample sizes, limited number of available studies, and substantial heterogeneity across studies. Further research is needed to determine whether specific sleep measures may better distinguish SZA from other psychiatric conditions.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 4","pages":"52900"},"PeriodicalIF":2.9,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}